Literature DB >> 32457184

Challenges and Approaches to Measuring Repeat Fecal Immunochemical Test for Colorectal Cancer Screening.

Caitlin C Murphy1,2,3, Ethan A Halm4,2,3, Celette Sugg Skinner4,3, Bijal A Balasubramanian3,5, Amit G Singal4,2,3.   

Abstract

BACKGROUND: Colorectal cancer screening with fecal immunochemical testing (FIT) can reduce colorectal cancer-related mortality. Effectiveness of FIT may be compromised when patients do not adhere to a regular schedule. However, having no standard measure of repeat FIT presents challenges for assessing effectiveness across populations and settings. We compared three measures of repeat FIT in a large, integrated health care system in Dallas, Texas.
METHODS: We identified 18,257 patients age-eligible (50-60 years) for FIT in January 1-December 31, 2010 and followed over four rounds of screening. Measures included: (i) repeat FIT in prior screeners, or completion of FIT within 9-15 months of the previous; (ii) yes-no patterns, whereby patients were assigned yes or no in 9-15 month windows; and 3) proportion of time covered (PTC), or the amount of time patients were up-to-date with screening relative to time eligible.
RESULTS: Repeat FIT varied by measure. Using a prior screeners measure, 15.8% of patients with a normal FIT in round 1 completed repeat FIT in round 2. Repeat FIT was notably higher (52.3%) using PTC. The most common yes-no pattern was YNNN or "one-and-done," and only 9.4% of patients completed two consecutive FITs across all rounds (YYNN).
CONCLUSIONS: Different measures of repeat FIT yielded a range of estimates, making comparison across studies difficult. Researchers should weigh the advantages and disadvantages of each measure and select the most appropriate to their research question. IMPACT: Our study highlights the need for future research of repeat FIT measures that best approximate screening effectiveness. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32457184      PMCID: PMC7416474          DOI: 10.1158/1055-9965.EPI-20-0230

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

1.  Are there gender differences in colorectal cancer test use prevalence and correlates?

Authors:  Amy McQueen; Sally W Vernon; Helen I Meissner; Carrie N Klabunde; William Rakowski
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-04       Impact factor: 4.254

2.  The effect of HEDIS measurement of colorectal cancer screening on insurance plans in Pennsylvania.

Authors:  Mona Sarfaty; Ronald E Myers
Journal:  Am J Manag Care       Date:  2008-05       Impact factor: 2.229

Review 3.  Organized colorectal cancer screening in integrated health care systems.

Authors:  Theodore R Levin; Laura Jamieson; Daniel A Burley; Juan Reyes; Michael Oehrli; Cindy Caldwell
Journal:  Epidemiol Rev       Date:  2011-06-27       Impact factor: 6.222

4.  Trends in colorectal cancer test use among vulnerable populations in the United States.

Authors:  Carrie N Klabunde; Kathleen A Cronin; Nancy Breen; William R Waldron; Anita H Ambs; Marion R Nadel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-08       Impact factor: 4.254

5.  Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.

Authors:  Amy B Knudsen; Ann G Zauber; Carolyn M Rutter; Steffie K Naber; V Paul Doria-Rose; Chester Pabiniak; Colden Johanson; Sara E Fischer; Iris Lansdorp-Vogelaar; Karen M Kuntz
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

6.  Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs.

Authors:  Vivy T Cusumano; Folasade P May
Journal:  J Gen Intern Med       Date:  2020-03-03       Impact factor: 5.128

Review 7.  Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.

Authors:  Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

8.  Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.

Authors:  Ann G Zauber; Sidney J Winawer; Michael J O'Brien; Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Benjamin F Hankey; Weiji Shi; John H Bond; Melvin Schapiro; Joel F Panish; Edward T Stewart; Jerome D Waye
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

9.  Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening.

Authors:  R J C Steele; I Kostourou; P McClements; C Watling; G Libby; D Weller; D H Brewster; R Black; F A Carey; C Fraser
Journal:  BMJ       Date:  2010-10-27

10.  Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.

Authors:  Amit G Singal; Douglas A Corley; Aruna Kamineni; Michael Garcia; Yingye Zheng; Paul V Doria-Rose; Virginia P Quinn; Christopher D Jensen; Jessica Chubak; Jasmin Tiro; Chyke A Doubeni; Nirupa R Ghai; Celette Sugg Skinner; Karen Wernli; Ethan A Halm
Journal:  Am J Gastroenterol       Date:  2018-02-27       Impact factor: 10.864

View more
  4 in total

1.  Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance.

Authors:  Amit G Singal; Sarah Reddy; Himani Radadiya Aka Patel; Deyaun Villarreal; Aisha Khan; Yan Liu; Vanessa Cerda; Nicole E Rich; Caitlin C Murphy; Jasmin A Tiro; Jennifer R Kramer; Ruben Hernaez
Journal:  Clin Gastroenterol Hepatol       Date:  2021-12-10       Impact factor: 13.576

2.  Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort.

Authors:  Lesley-Ann Miller-Wilson; Lila J Finney Rutten; Jack Van Thomme; A Burak Ozbay; Paul J Limburg
Journal:  Int J Colorectal Dis       Date:  2021-05-21       Impact factor: 2.571

3.  A Centralized Program with Stepped Support Increases Adherence to Colorectal Cancer Screening Over 9 Years: a Randomized Trial.

Authors:  Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon
Journal:  J Gen Intern Med       Date:  2021-05-28       Impact factor: 6.473

4.  Adherence to fecal immunochemical test screening among adults at average risk for colorectal cancer.

Authors:  Deborah A Fisher; Nicole Princic; Lesley-Ann Miller-Wilson; Kathleen Wilson; Kathryn DeYoung; A Burak Ozbay; Paul Limburg
Journal:  Int J Colorectal Dis       Date:  2021-11-02       Impact factor: 2.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.